Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
University of Miami
mi
from
Miami, FL
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
South Suburban Neurology
mi
from
Flossmoor, IL
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
South Suburban Neurology
mi
from
Flossmoor, IL
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Norton Neuroscience Institute - Norton Neurology Services MS Center
mi
from
Louisville, KY
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Norton Neuroscience Institute - Norton Neurology Services MS Center
mi
from
Louisville, KY
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
University of Maryland
mi
from
Baltimore, MD
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Univ of Minnesota
mi
from
Minneapolis, MN
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Judith Jaffe Multiple Sclerosis Center: Weill Cornell Medical College
mi
from
New York, NY
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Judith Jaffe Multiple Sclerosis Center: Weill Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Univ of North Carolina
mi
from
Chapel Hill, NC
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Providence St. Vincent Medical Center
mi
from
Portland, OR
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Providence St. Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
The Neurology Foundation, Inc.
mi
from
Providence, RI
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
The Neurology Foundation, Inc.
mi
from
Providence, RI
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Advanced Neurosciences Institute
mi
from
Franklin, TN
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Advanced Neurosciences Institute
mi
from
Franklin, TN
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Benaroya Research Institute at Virginia Mason
mi
from
Seattle, WA
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Benaroya Research Institute at Virginia Mason
mi
from
Seattle, WA
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Louisiana State Univ.
mi
from
Shreveport, LA
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Louisiana State Univ.
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Brigham and Women's Hosp
mi
from
Boston, MA
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Neurology Specialists
mi
from
Dayton, OH
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Neurology Specialists
mi
from
Dayton, OH
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Ottawa Hospital Research Institute
mi
from
Ottawa,
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Ottawa Hospital Research Institute
mi
from
Ottawa,
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Gilbert, AZ
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Long Beach, CA
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Miami, FL
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Avon, IN
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Avon, IN
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Franklin, IN
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Franklin, IN
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Overland Park, KA
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Auburn, ME
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Auburn, ME
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Asheville, NC
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Charlotte, NC
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Raleigh, NC
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Wilmington, NC
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Dayton, OH
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Dallas, TX
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Wenatchee, WA
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
mi
from
Leuven,
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
mi
from
Leuven,
Click here to add this to my saved trials
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Atlanta, GA
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Lexington, KY
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Baltimore, MD
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Raleigh, NC
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Akron, OH
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Cleveland, OH
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Nashville, TN
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Research Site
mi
from
Sint-Truiden,
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Research Site
mi
from
Sint-Truiden,
Click here to add this to my saved trials
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated:  8/10/2016
Clinical Research Facility
mi
from
Gilbert, AZ
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated: 8/10/2016
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated:  8/10/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated: 8/10/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated:  8/10/2016
Clinical Research Facility
mi
from
Tucson, AZ
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated: 8/10/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated:  8/10/2016
Clinical Research Facility
mi
from
Boulder, CO
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated: 8/10/2016
Clinical Research Facility
mi
from
Boulder, CO
Click here to add this to my saved trials
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated:  8/10/2016
Clinical Research Facility
mi
from
Fort Collins, CO
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated: 8/10/2016
Clinical Research Facility
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated:  8/10/2016
Clinical Research Facility
mi
from
Dover, DE
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated: 8/10/2016
Clinical Research Facility
mi
from
Dover, DE
Click here to add this to my saved trials
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated:  8/10/2016
Clinical Research Facility
mi
from
Newark, DE
Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a
An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Status: Enrolling
Updated: 8/10/2016
Clinical Research Facility
mi
from
Newark, DE
Click here to add this to my saved trials